Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective sampling in intravenously treated oncology patients: monoclonal antibodies

Next Previous
Trial Profile

Prospective sampling in intravenously treated oncology patients: monoclonal antibodies

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Trastuzumab (Primary)
  • Indications Cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
  • Focus Biomarker; Pharmacodynamics
  • Acronyms MULTOMAB

Most Recent Events

  • 18 Aug 2022 Results of an analysis assessed the association between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment published in the European Journal of Cancer
  • 21 Sep 2020 Results (N=107), of metastatic melanoma cohort presented at the 45th European Society for Medical Oncology Congress
  • 31 May 2020 Results (N=107), subgroup analyses in metastatic melanoma patients group assessing clinical value of noninvasive biomarkers reflecting a collagen-rich stroma, presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top